Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Upgraded by StockNews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Thursday.

JAZZ has been the subject of several other research reports. Barclays decreased their price target on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Piper Sandler raised their price target on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Stifel Nicolaus raised their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Truist Financial reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $190.00.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $106.73 on Thursday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The stock has a market capitalization of $6.73 billion, a P/E ratio of 22.01, a PEG ratio of 1.64 and a beta of 0.62. The company has a 50 day moving average price of $108.93 and a 200 day moving average price of $116.77. Jazz Pharmaceuticals has a fifty-two week low of $103.01 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The company had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Equities research analysts forecast that Jazz Pharmaceuticals will post 15.35 EPS for the current year.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the sale, the executive vice president now directly owns 36,629 shares in the company, valued at approximately $4,016,369.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of JAZZ. Allspring Global Investments Holdings LLC increased its stake in Jazz Pharmaceuticals by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock valued at $1,937,000 after purchasing an additional 99 shares during the period. Waterfront Wealth Inc. increased its stake in Jazz Pharmaceuticals by 1.2% in the fourth quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock valued at $1,062,000 after purchasing an additional 103 shares during the period. ProShare Advisors LLC increased its stake in Jazz Pharmaceuticals by 1.4% in the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock valued at $896,000 after purchasing an additional 105 shares during the period. Prime Capital Investment Advisors LLC increased its stake in Jazz Pharmaceuticals by 4.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after purchasing an additional 108 shares during the period. Finally, Ontario Teachers Pension Plan Board increased its stake in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock valued at $3,659,000 after purchasing an additional 108 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.